<DOC>
	<DOCNO>NCT00239499</DOCNO>
	<brief_summary>The primary objective study estimate comparative bronchodilator effect size variability tiotropium ( Spiriva , 18 µg q.d . ) free combination salmeterol ( Serevent , 50 µg b.i.d . ) fluticasone ( Flixotide , 250 µg b.i.d . ) COPD patient . International COPD guideline preserve milder stage disease ( GOLD stage I IIa ) bronchodilator recommend addition inhaled corticosteroid patient document spirometric response inhale corticosteroid patient post-bronchodilator FEV1 le 50 % predict , suffer frequent exacerbation require oral course corticosteroid . Recently publish report indicate additional bronchodilator efficacy may achieve long-acting beta agonist combine inhaled corticosteroid . Steady state bronchodilation achieve within one week drug combination . However , result study consistent , since inclusion criterion employ different utilised previously conduct tiotropium study , difficult generalise observe effect general COPD population . In addition , comparative data available average response 12 daytime hour COPD patient active need bronchodilation . 12 hour correspond dose interval salmeterol fluticasone .</brief_summary>
	<brief_title>Pilot Study Comparing Tiotropium ( Spiriva ) Salmeterol ( Serevent ) Plus Fluticasone ( Flixotide ) Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This six-week , multi-centre , randomised , double-blind , triple-dummy , parallel group pilot study compare bronchodilator efficacy safety long-acting bronchodilator tiotropium ( Spiriva , 18 µg q.d . ) free combination fluticasone ( Flixotide , 250 µg b.i.d . ) salmeterol ( Serevent , 50 µg b.i.d . ) patient COPD . Following initial screen Visit 1 , subject enter two-week run-in period record daily rescue salbutamol use Patient Daily Diary Card . At Visit 1 , pre-dose post-bronchodilator pulmonary function test ( PFT ) measure . Four inhalation ipratropium ( 20 µg per puff ) four inhalation salbutamol ( 100 µg per puff ) administer 60 minute prior obtain post-bronchodilator PFT measurement . At Visit 2 , pre-dose PFT perform prior first administration trial medication . Treatment blind study medication ( tiotropium fluticasone + salmeterol ) start morning Visit 2 ( Day 1 ) . After three week treatment , Visit 3 ( Day 22 ) , pre-dose FEV1 FVC measure , patient compliance check re-supply study medication dispense . After six week treatment , Visit 4 ( Day 43 ) , 12 hour profile PFTs obtain . Study Hypothesis : As pilot trial investigate efficacy safety tiotropium ( 18 µg q.d . ) compare free combination fluticasone ( 250 µg b.i.d . ) salmeterol ( 50 µg b.i.d . ) , formal hypothesis test perform . However , underlie hypothesis trial tiotropium superior free combination respect primary efficacy endpoint FEV1AUC0-12 ( area curve time period 0 12 hour ) . Comparison ( ) : At least 100 male female outpatient clinical spirometric evidence chronic obstructive pulmonary disease ( COPD ) enter study . Patients randomly assign receive either tiotropium inhalation capsule 18 µg q.d. , salmeterol 50 µg oral inhalation b.i.d . free combination fluticasone 250 µg oral inhalation b.i.d . double-blind triple-dummy fashion .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : All patient must diagnosis chronic obstructive pulmonary disease accord GOLD criterion must meet follow spirometric criterion : Patients must relatively stable airway obstruction postbronchodilator FEV1 &lt; 80 % predict normal FEV1/FVC &lt; 70 % Visit 1 , predose FEV1 &lt; 65 % predict Visit 2 . Male female patient 40 year age old . There upper age limit . Patients must current exsmokers smoke history 10 packyears . Exclusion criterion : Patients significant disease COPD . Patients history asthma , allergic rhinitis atopy total blood eosinophil count equal 600/mm3 . Patients treat commercially available tiotropium ( Spiriva® ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>